FDAnews
www.fdanews.com/articles/72141-dow-and-cytogen-agree-to-develop-psma-antibody

Dow and Cytogen Agree to Develop PSMA Antibody

May 10, 2005

Cytogen Corporation, a product-driven biopharmaceutical company, and Dowpharma contract manufacturing services, a business unit of The Dow Chemical Company, announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers. Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

PharmaLive (http://www.pharmalive.com/News/index.cfm?articleid=238039&categoryid=15)